FRX and FENC Related Headlines
Go Back- Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
- Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
- Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
- Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
- Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
- Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
- Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
- Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
- Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
- Fennec Pharmaceuticals closes $5 million private share offering in Canada
- Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
- Fennec Pharmaceuticals raises $40.25 million in public offering
- Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
- Fennec Pharmaceuticals plans private offering of common shares
- Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
- Fennec Pharmaceuticals prices $35 million share offering at $7.50
- Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
- Fennec Pharmaceuticals announces public offering of common shares
- Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
- Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
- Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
FRX and FENC Related Press Releases
Go Back- Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
- Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
- Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
- Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
- Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
- Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
- Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
- Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
- Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
- Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
- Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
- Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
- Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
- Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
- Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
- Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
FRX and FENC Related SEC Filings
Go Back- Form 8-K FENNEC PHARMACEUTICALS For: Mar 16
- Form 4 FENNEC PHARMACEUTICALS For: Feb 18 Filed by: Andrade Robert
- Form S-8 FENNEC PHARMACEUTICALS
- Form 8-K FENNEC PHARMACEUTICALS For: Mar 04
- Form 4 FENNEC PHARMACEUTICALS For: Feb 28 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Feb 28 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 8-K FENNEC PHARMACEUTICALS For: Feb 20
- Form 4 FENNEC PHARMACEUTICALS For: Feb 18 Filed by: Hackman Jeffrey S.
- Form 4 FENNEC PHARMACEUTICALS For: Feb 18 Filed by: Andrade Robert
- Form SCHEDULE 13G/A FENNEC PHARMACEUTICALS Filed by: Sonic Fund II, L.P.
- Form SCHEDULE 13G/A FENNEC PHARMACEUTICALS Filed by: Rosalind Advisors, Inc.
- Form 4 FENNEC PHARMACEUTICALS For: Feb 02 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jan 31 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Jan 31 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Jan 31 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jan 23 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Jan 15 Filed by: Andrade Robert
- Form SCHEDULE 13G/A FENNEC PHARMACEUTICALS Filed by: Southpoint Capital Advisors LP
- Form 4 FENNEC PHARMACEUTICALS For: Jan 07 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Dec 31 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Dec 31 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Dec 24 Filed by: Southpoint Capital Advisors LLC
- Form 8-K FENNEC PHARMACEUTICALS For: Dec 09
- Form 4 FENNEC PHARMACEUTICALS For: Dec 05 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Dec 01 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Dec 01 Filed by: Andrade Robert
- Form 8-K FENNEC PHARMACEUTICALS For: Dec 02
- Form 4 FENNEC PHARMACEUTICALS For: Nov 18 Filed by: Southpoint Capital Advisors LLC
- Form 8-K FENNEC PHARMACEUTICALS For: Nov 13
- Form S-8 FENNEC PHARMACEUTICALS
- Form 8-K FENNEC PHARMACEUTICALS For: Nov 17
- Form 424B5 FENNEC PHARMACEUTICALS
- Form 4 FENNEC PHARMACEUTICALS For: Nov 14 Filed by: Southpoint GP, LP
- Form 424B5 FENNEC PHARMACEUTICALS
- Form 8-K FENNEC PHARMACEUTICALS For: Nov 13
- Form 424B5 FENNEC PHARMACEUTICALS
- Form SCHEDULE 13G FENNEC PHARMACEUTICALS Filed by: Rosalind Advisors, Inc.
- Form 10-Q FENNEC PHARMACEUTICALS For: Sep 30
- Form 4 FENNEC PHARMACEUTICALS For: Nov 05 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Oct 31 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Oct 31 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Oct 10 Filed by: RALLIS CHRIS A
- Form 144 FENNEC PHARMACEUTICALS Filed by: RALLIS CHRIS A
- Form 4 FENNEC PHARMACEUTICALS For: Oct 07 Filed by: Southpoint Capital Advisors LLC
- Form 4 FENNEC PHARMACEUTICALS For: Oct 08 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Oct 06 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Sep 05 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Sep 04 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Aug 31 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Aug 31 Filed by: Andrade Robert
- Form 10-Q FENNEC PHARMACEUTICALS For: Jun 30
- Form 4 FENNEC PHARMACEUTICALS For: Aug 05 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jul 31 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jul 31 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Jul 07 Filed by: RALLIS CHRIS A
- Form 4 FENNEC PHARMACEUTICALS For: Jul 03 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jun 30 Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jun 30 Filed by: Andrade Robert
- Form 4 FENNEC PHARMACEUTICALS For: Jun 05 Filed by: Raykov Rosty
- Form 144 FENNEC PHARMACEUTICALS Filed by: Raykov Rosty
- Form 4 FENNEC PHARMACEUTICALS For: Jun 03 Filed by: RALLIS CHRIS A
- Form 4 FENNEC PHARMACEUTICALS For: Jun 03 Filed by: Cook Jodi A
- Form 4 FENNEC PHARMACEUTICALS For: Jun 03 Filed by: Islam Khalid
- Form 4 FENNEC PHARMACEUTICALS For: Jun 03 Filed by: Brughera Marco Maria
